09 June 2015 - Neurolixis CEO to present NLX-112 data at Parkinson and Movement Disorders Society Congress

Dr. Mark A. Varney , PhD, Chief Executive Officer of Neurolixis, will present the latest preclinical data on NLX-112 at the 19th International Congress of Parkinson’s Disease and Movement Disorders to be held on June 14-18, 2015 in San Diego, California. The poster (#342) is entitled “ NLX-112, a novel candidate for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat .” NLX-112  (also known as befiradol) exhibits a promising profile in rat models of Parkinson’s disease, completely abolishing dyskinesias and also exhibiting potent antidepressant-like activity. Investigation of NLX-112 has been conducted with support from the  Michael. J. Fox Foundation (see previous announcement ) and results have recently been published ( Iderberg et al., Experimental Neurology, 2015 ). Neurolixis is pursuing opportunities to partner the clinical development of  NLX-112 – contact us for further information. For full details of the Parkinson and Movement Disorders Society congress see the  meeting website .

The release as fetched from its publisher. neurolixis.com ↗